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Abstract
Background: Normal cells possess a limited proliferative life span after which they enter a state of
irreversible growth arrest. This process, known as replicative senescence, is accompanied by
changes in gene expression that give rise to a variety of senescence-associated phenotypes. It has
been suggested that these gene expression changes result in part from alterations in the histone
acetylation machinery. Here we examine the influence of HDAC inhibitors on the expression of
senescent markers in pre- and post-senescent WI-38 cells.
Results: Pre- and post-senescent WI-38 cells were treated with the HDAC inhibitors butyrate or
trichostatin A (TSA). Following HDAC inhibitor treatment, pre-senescent cells increased p21WAF1
and β-galactosidase expression, assumed a flattened senescence-associated morphology, and
maintained a lower level of proteasome activity. These alterations also occurred during normal
replicative senescence of WI-38 cells, but were not accentuated further by HDAC inhibitors. We
also found that HDAC1 levels decline during normal replicative senescence.
Conclusion: Our findings indicate that HDACs impact numerous phenotypic changes associated
with cellular senescence. Reduced HDAC1 expression levels in senescent cells may be an
important event in mediating the transition to a senescent phenotype.
Background
Normal somatic cells possess a limited proliferative life
span after which they enter a state of irreversible growth
arrest. This process, known as replicative senescence, can
be signaled by shortened telomeres that result from
repeated rounds of DNA replication in the absence of tel-
omerase expression. Once the telomeres erode to an aver-
age size of 4–6 kilobases, senescence is triggered and cells
stop dividing [1,2]. Replicative senescence plays an
important role in maintaining the structural integrity of
tissues by limiting the excessive clonal expansion of cells
[3,4]. However, the accumulation of senescent cells is also
believed to contribute to the age-related decline in tissue
function [5]. Replicative senescence can therefore be
viewed as both a mechanism of tumor suppression and a
contributor in pathologies associated with age. The role of
replicative senescence in tumorigenesis is highlighted by
the fact that the most common mutations in human can-
cers occur in genes encoding p53 and members of the pRB
pathway, which are the critical effectors of replicative
senescence [4,6,7].
A number of fundamental metabolic and biochemical
changes occur as a cell enters senescence and begins to
age. Numerous studies have reported dramatic changes in
protein turnover. The proteasome, the primary non-lyso-
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proteins including misfolded, oxidized and ubiquitinated
proteins, has been reported to decline in function with age
[8-13]. Several reports have indicated that the expression
of certain proteasome subunits drops after cells enter rep-
licative senescence [14-17]. In addition, proteasome inhi-
bition, or "clogging", has been observed as aging cells
accumulate damaged proteins [12,13,18]. The resulting
drop in protein turnover may contribute to the accumula-
tion of protein deposits, such as lipofuscin, which can fur-
ther compromise cell function [19]. In addition, the drop
in proteasome activity is likely to alter the activity of
numerous cellular signal transduction pathways that
involve the proteasome.
Replicative senescence is accompanied by many changes
in gene expression that contribute to the senescence-asso-
ciated phenotypes. Of particular importance are the cell
cycle inhibitors p16INK4a and p21WAF1, which are induced
upon replicative senescence to halt cell proliferation
[20,21]. Interestingly, many genes involved in the regula-
tion of cellular growth arrest and differentiation are regu-
lated by histone acetylation. For example, in proliferating
fibroblasts, the stable association of HDAC1 with the Sp1/
Sp3 transcription factors bound to the p21WAF1 promoter
suppresses p21WAF1 expression. Upon senescence, HDAC1
is displaced from to the p21WAF1 promoter, due in part to
the actions of p53 [22].
HDAC inhibitors have long been known to induce differ-
entiation, growth arrest, and apoptosis in cancer cells [23-
25]. The aberrant utilization of HDACs is believed to be a
contributing factor in carcinogenesis. However, only
recently have HDAC inhibitors been shown to induce pre-
mature senescence in normal human fibroblasts [26,27].
HDACs may therefore play a critical role in modulating
HDAC inhibition induces markers of senescenceFigure 1
HDAC inhibition induces markers of senescence. (A) Butyrate and TSA induce the expression of the senescence-asso-
ciated cell cycle inhibitor protein p21WAF1. Proliferating WI-38 cells were treated with butyrate (BA) or TSA for 24 hours. 
Cytosolic extracts were prepared and equivalent protein levels were analyzed by immunoblot using an anti-p21WAF1 antibody. 
Untreated samples (0 hours) consisted of cytosolic extracts prepared from naïve cells. Results are shown in triplicate. (B) 
Butyrate and TSA rapidly induce senescent-like morphologies in young WI-38 cells. Proliferating WI-38 cells were treated with 
butyrate or TSA for 0, 24, 48, and 72 hours, as indicated. Phase contrast images of cell morphology were taken at 100 × mag-
nification. An image of WI-38 cells propagated to replicative senescence is also shown.Page 2 of 11
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tribute to the cellular changes associated with transforma-
tion. Here we examine the interplay between cellular
HDAC activity and a number of phenotypic changes that
accompany cell senescence. We find that replicative senes-
cence is accompanied by a drop in cellular HDAC1 expres-
sion, the activation of the cell cycle inhibitory protein
p21WAF1, and a reduction in cellular proteasome activity
and subunit expression. The critical role of HDACs in reg-
ulating these events is supported by the finding that
HDAC inhibitors selectively trigger these changes in pre-
senescent, but not post-senescent cells. Our findings indi-
cate that a drop in HDAC expression may be a critical
event in mediating the transition from a proliferating to a
senescent phenotype.
Results
HDAC inhibitors induce a senescence-like phenotype in 
proliferating WI-38 cells
HDAC inhibitors can induce growth arrest in many cell
types, and have recently been reported to induce a senes-
cence-like state in normal human fibroblasts [26,27].
Therefore, we sought to determine if the HDAC inhibitors
butyrate and TSA could induce premature senescence in
proliferating WI-38 cells. One molecular marker of senes-
cence in normal human fibroblasts is p21WAF1 expression
[28]. As shown in Figure 1A, treatment with butyrate or
TSA for 24 hours induced the expression of p21WAF1 in
proliferating WI-38 cells. Distinct morphological changes
also occurred when WI-38 cells enter replicative senes-
cence. Senescent cells became larger and assumed irregu-
lar shapes, while proliferating WI-38 cells formed long
and striated parallel arrays (Figure 1B). As shown in Figure
1B, treatment of young WI-38 cells with HDAC inhibitors
butyrate or TSA caused cells to rapidly acquire a senescent-
like morphology.
Another biomarker for replicative senescence is senes-
cence-associated-β-galactosidase (SA-β-gal) activity [29].
Young WI-38 cells were cultured for 14 days in 0.5 mM
butyrate or 9 days in 0.5 µM TSA. These concentrations
allowed for the prolonged exposure of WI-38 cells to the
HDAC inhibitors with minimal cytotoxicity. As shown in
Figure 2, young WI-38 cells cultured in the presence of
either HDAC inhibitor acquired the perinuclear staining
for SA-β-gal activity normally associated with senescent
HDAC inhibition induces the senescence-associated-β-glacatosidase (SA-β-gal) activity in proliferating WI-38 cellsFigure 2
HDAC inhibition induces the senescence-associated-β-glacatosidase (SA-β-gal) activity in proliferating WI-38 
cells. Proliferating WI-38 cells were propagated for 14 days in 0.5 mM butyrate (Proliferating WI-38; Butyrate) or 9 days in 0.5 
µM TSA (Proliferating WI-38; TSA) and stained for SA-β-gal activity. The level of SA-β-gal staining was also determined in 
untreated young WI-38 cells propagated in parallel (Proliferating WI-38; Control), as well as WI-38 cells propagated to replica-
tive senescence (Senescent WI-38; Control). Phase contrast images are shown in duplicate at 100 × magnification.Page 3 of 11
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parallel had no SA-β-gal activity (Figure 2). This data fur-
ther supports the findings that HDAC inhibition induces
a senescent-like phenotype in proliferating fibroblasts
[26,27].
Proteasome activity is reduced in senescent WI-38 cells
Declines in proteasome function during senescence and
aging have been observed in cultured cells and in tissues
from a variety of organisms [8-10,14,15,17]. Our aim was
to verify and characterize the changes in proteasome activ-
ity following senescence in the human fibroblast WI-38
cell line. Cytosolic extracts prepared from proliferating
and senescent WI-38 cells were tested for proteasome
activity using the synthetic substrate Suc-LLVY-AMC [30].
As shown in Figure 3A, proteasome activity was signifi-
cantly lower (reduced by ~30%) in the older WI-38 cells.
Since a decrease in proteasome activity may also cause a
general increase in the presence of polyubiqitinated pro-
teins, cytsolic extracts from proliferating and senescent
WI-38 cells were analyzed by immunoblotting for polyu-
biquitinated proteins. As indicated in Figure 3B, the accu-
mulation of high molecular weight ubiquitin-conjugated
proteins was accentuated in the senescent WI-38 cells,
which is consistent with a drop in proteasome activity.
Previous reports have documented that certain proteas-
ome subunits are down-regulated in senescent WI-38 cells
[14,15]. However, these analyses were limited to only a
select subset of proteasome subunits. We therefore ana-
lyzed the expression of each constitutive β-type subunit to
further characterize differences in proteasome subunit
expression between proliferating and senescent cells (Fig-
ure 4). As shown in Figure 4, senescent WI-38 cells
expressed lower levels of the three catalytic proteasome
subunits: β5 (X), β1 (Y), and β2 (Z). However, the expres-
sion levels of the other β-type subunits did not change in
the older cells. Figure 4 also shows the increased expres-
sion of p21WAF1 in senescent WI-38 cells [20]. The protein
expression levels of the β5 subunit were additionally
quantified by optical densitometry from immunoblots
(Figure 5). The β5 protein levels were reduced by ~30% in
senescent WI-38 cells, which corresponds to the ~30%
decline in proteasome activity (as shown in Figure 3A).
Expression levels of the β-type proteasome subunits in prolif-erating and sene cent WI 38 cellsFigure 4
Expression levels of the β-type proteasome subunits 
in proliferating and senescent WI-38 cells. Cytosolic 
extracts were prepared from proliferating and senescent WI-
38 cells. Samples were analyzed by immunoblot using anti-
bodies specific for each of the β-type proteasome subunits. 
Actin served as a loading control. Levels of p21WAF1 (p21) 
were also determined to serve as an inducible marker for 
replicative senescence. Results from duplicate cultures are 
shown.
Proteasome activity is reduced in senescent WI-38 cellsFigure 3
Proteasome activity is reduced in senescent WI-38 
cells. (A) Cell lysates were prepared from proliferating or 
senescent WI-38 cells. Protein concentrations were normal-
ized and proteasome activity was determined using a syn-
thetic fluorogenic substrate (± standard error; n = 4). The 
reduction in proteasome activity was found to be significant 
in the older cells (**, p < 0.01). (B) Polyubiquitinated pro-
teins found in the cytosolic extracts of proliferating and 
senescent WI-38 cells. Sample concentrations were normal-
ized and the level of polyubiquitin-protein conjugates was 
determined by immunoblot using an antibody specific for 
ubiquitin.Page 4 of 11
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The expression of p21WAF1 is regulated by aceytlation and
readily activated by HDAC inhibitors [31,32]. We there-
fore determined the effect of HDAC inhibitors on p21WAF1
expression in proliferating and senescent WI-38 cells. As
shown in Figure 6A, treatment with HDAC inhibitors
butyrate or TSA induced p21WAF1 expression in proliferat-
ing WI-38 cells. However, in senescent cells the endog-
enous levels of p21WAF1 were high and not further
enhanced by either HDAC inhibitor (Figure 6A). These
data suggest that p21WAF1activation in senescent cells may
result from a reduction in cellular HDAC activity.
HDAC inhibitors have also been reported to suppress pro-
teasome activity and subunit expression in several trans-
formed cell lines [33-35]. We hypothesized that HDAC
inhibitors may suppress proteasome activity in proliferat-
ing WI-38 cells, as well. Cytosolic extracts were prepared
from young WI-38 cells treated with butyrate or TSA for 0,
24, 48, and 72 hours. The synthetic substrate Suc-LLVY-
AMC was then utilized to measure proteasome activity in
each sample. As shown in Figure 6B, proteasome activity
decreased in young WI-38 cells treated with either
butyrate or TSA. To determine if senescent WI-38 cells
were also sensitive to HDAC inhibitor-induced proteas-
ome suppression, the proteasome activity of senescent
WI-38 cells was analyzed following butyrate or TSA treat-
ment. Although proteasome activity was lower in senes-
cent WI-38 cells (as shown in Figure 3A), it was
significantly less sensitive to the inhibitory effects of the
HDAC inhibitors (Figure 6B). This data suggests that rep-
licative senescence and HDAC inhibitor-induced senes-
cence impacts proteasome activity through a common
pathway.
Reduced expression of the β5 proteasome subunit in 
proliferating WI-38 cells by HDAC inhibitors
We determined whether the HDAC inhibitors butyrate
and TSA could suppress the expression of the catalytic β5
subunit of the proteasome in proliferating WI-38 cells.
The immunoblots in Figure 7A indicate that β5 expression
levels decreased in these cells following butyrate or TSA
treatments. The expression levels of the β5 subunit were
additionally quantified by optical densitometry from
immunoblots (Figure 7B). This data indicates that
reduced proteasome activity following HDAC inhibition
(Figure 6B) may be due in part to reduced proteasome
subunit expression.
HDAC1 is down-regulated in senescent WI-38 cells
The class I histone deacetylase protein HDAC1 is a com-
ponent of the corepressor complex involved in suppress-
ing the transcription of p21WAF1 and other cell cycle
inhibitory genes [22]. We therefore determined if HDAC1
expression was altered upon replicative senescence. As
shown in Figure 8, HDAC1 levels decreased in senescent
WI-38 cells. (It should be noted that HDAC1 is predomi-
nantly a nuclear protein, but diffuses into the cyoplasmic
fraction during protein extraction.) The levels of another
class I histone deacetylase, HDAC3, was found to be
equivalent in pre- and post-senescent cells (Figure 8). The
drop in HDAC1 expression may contribute to the induc-
tion of p21WAF1 in senescent WI-38 cells (as shown in Fig-
ure 4; panel p21). Likewise, the decline in HDAC1 may
contribute to the appearance of other senescent pheno-
types, such as a drop in proteasome activity.
Discussion
Replicative senescence marks the end of the proliferative
life span of normal cells. This is accompanied by distinct
alterations in the pattern of gene expression. It has been
suggested that changes in gene expression during senes-
cence and aging may result in part from alterations in pro-
tein acetylation [36-38]. Figure 9 illustrates a potential
mechanism by which HDACs (e.g. HDAC1) contribute to
the senescence phenotype. As WI-38 cells senesce, HDAC
activity decreases to facilitate changes in gene expression.
Reductions in HDAC levels, in association with increased
transcriptional activity of p53 in senescent cells, contrib-
utes to the induction of p21WAF1 expression and subse-
Quantified levels of the β5 proteasome subunit and actin protein in proliferating and senescent WI-38 cellsFigure 5
Quantified levels of the β5 proteasome subunit and 
actin protein in proliferating and senescent WI-38 
cells. Cytosolic extracts were prepared and equivalent pro-
tein levels were analyzed for β5 subunit expression by immu-
noblotting. Actin levels served as a loading control. The 
graphical display indicates the relative intensities of β5 and 
actin levels determined by optical densitometry from corre-
sponding immunoblots (± standard error; n = 3). The decline 
in β5 levels was found to be significant in senescent cells (**, 
p < 0.01).Page 5 of 11
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HDACs contributing to the age-related decline in proteas-
ome activity, since HDAC inhibitors can reduce proteas-
ome expression and activity [33-35,41,42].
The identification of HDACs as a component in replica-
tive senescence, and hence growth arrest, is interesting
because data has shown that HDACs can promote tumor
growth and stem cell proliferation. For example, it has
been reported that HDAC1 overexpression occurs in 68%
of primary human gastric cancer, and contributes to col-
ony formation and proliferation of prostate and breast
cancer cells [43-45]. Some transformed cell types may
exaggerate the expression of HDACs to circumvent repli-
cative senescence. In this regard, cancer cells are similar to
stem cells, where HDAC1 is required for full cellular
Senescent WI-38 cells are resistant to the effects of HDAC inhibitionFigure 6
Senescent WI-38 cells are resistant to the effects of HDAC inhibition. (A) Butyrate and TSA did not further enhance 
the expression of cell cycle inhibitor protein p21WAF1 in senescent WI-38 cells. Proliferating and senescent WI-38 cells were 
treated with butyrate (BA) or TSA for 24 hours, as indicated. Cytosolic extracts were prepared and equivalent protein levels 
were analyzed by immunoblot using an antibody specific for p21WAF1. Actin served as a loading control and was determined by 
immunoblotting for the actin protein. Control samples (0 hours) consisted of cytosolic extracts prepared from untreated cells. 
(B) The effect of HDAC inhibitors on proteasome activity in proliferating and senescent WI-38 cells. Cytoslic extracts were 
prepared from proliferating (Young;◆) and senescent (Old; ) WI-38 cells treated with butyrate (+ Butyrate) or TSA (+ TSA) 
for 0, 24, 48 and 72 hours, as indicated. Equivalent protein concentrations were determined and analyzed for proteasome 
activity using a synthetic fluorogenic substrate (± standard error; n = 4; values of non-treated samples set to 1). Senescent cells 
were found to be significantly less responsive to proteasome inhibition by butyrate and TSA.Page 6 of 11
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replicative senescence, and the associated decline in
HDAC1 expression, has a tumor suppressing role [4,47].
It is not entirely clear how HDACs are regulating proteas-
ome subunit expression. In yeast, a common mode of
transcriptional regulation of the proteasomal subunits has
already been identified [48-50]. Nearly all the yeast subu-
nit homologs have been found to possess proteasome-
associated control elements within their promoters. The
transcription factor RPN4 has been identified as the com-
ponent within yeast involved in binding these elements to
modulate gene transcription [48]. Remarkably, no
homolog of RPN4 has been identified in humans. How-
ever, it is still possible that another common transcrip-
tional mechanism is shared amongst the catalytic
subunits in human cells. The activity of these putative reg-
ulatory proteins may be regulated by acetylation, such
HDAC inhibitors down-regulate β5 proteasome subunit expression in proliferating WI-38 cellsFigure 7
HDAC inhibitors down-regulate β5 proteasome subunit expression in proliferating WI-38 cells. (A) Proliferating 
WI-38 cells were treated with butyrate (BA) or TSA for 0, 24, 48, or 72 hours, as indicated. Cytosolic extracts were prepared 
and equivalent protein levels (determined by a Bradford assay) were analyzed by immunoblotting using an antibody specific for 
the β5 proteasome subunit. Actin served as a loading control. (B) Immunoblots from Figure 7A were quantified by optical den-
sitometry. The graphical display shows the relative levels of the β5 subunit (normalized to actin) from the corresponding 
immunoblots (± standard error; n = 3). The decline in β5 levels was found to be significant at the indicated time points (**, p < 
0.01).Page 7 of 11
(page number not for citation purposes)
BMC Cell Biology 2005, 6:37 http://www.biomedcentral.com/1471-2121/6/37that an increased level of acetylation reduces proteasome
subunit expression.
Our analysis of HDAC1 and HDAC3 indicates that repli-
cative senescence is not accompanied by a global decline
in HDAC expression. Rather, it appears to occur through
the down-regulation of HDAC1, and potentially other
HDACs. Other groups have also reported a senescence-
specific form of the HDAC2 protein [38]. In addition, the
NAD+-dependent Sir2 histone deacetylase has been iden-
tified to contribute to the replicative life-span in yeast,
thus suggesting that the mammalian Sir2-related class III
HDACs may contribute to senescence in normal human
cell types, as well [51,52]. It should be noted that it is not
clear if the decline in HDAC1 is a cause or a consequence
of replicative senescence. However, it seems reasonable to
hypothesize that age-related modulations in HDAC levels
could be a contributing factor in senescence. Further anal-
ysis of individual HDAC proteins may identify their indi-
vidual functions within the senescence machinery. Anti-
aging and anti-cancer strategies may be aimed at increas-
ing or decreasing the activity of specific HDAC proteins.
Conclusion
Our findings indicate that cellular HDAC activity regu-
lates numerous phenotypic changes associated with cellu-
lar senescence. Reduced cellular HDAC expression and
activity, in association with other events, may be impor-
tant for mediating the transition to a senescent pheno-
type.
Methods
Cell culture and treatments
The WI-38 human lung fibroblast cell line was purchased
from American Type Culture Collection (Manassas, VA).
Cells were propagated in minimal essential media con-
taining 2 mM L-glutamine and Earle's salts (E-MEM) sup-
plemented with 10% fetal bovine serum, 0.1 mM non-
essential amino acids, 1 mM Sodium Pyruvate, streptomy-
cin (50 mg/ml), and penicillin (50 U/ml). All medium
components were purchased from Invitrogen Life Tech-
nologies (Carlsbad, CA). WI-38 cells entered senescence at
about 50 CPD (Cumulative Population Doublings).
Early-passage WI-38 cells (CPD < 30) are referred to as
young or pre-senescent cells and displayed high prolifera-
tive potential. Late-passage WI-38 cells (CPD > 50) are
classified as old or post-senescent cells and exhibited very
low proliferative potential. Sodium butyrate (Sigma-
Aldrich, St. Louis, MO) was used at the final concentration
of 4 mM (unless stated otherwise). TSA (Calbiochem, San
Diego, CA) was used at a 2 µM concentration (unless
stated otherwise). Cells treated with TSA were given fresh
media supplemented with new TSA every 24 hours.
Immunoblotting
Cytosolic extracts were prepared as described in Inan et al.
[53]. For immunoblotting studies, 25 µg of cytoplasmic
protein (quantified by the Bio-Rad protein assay) was
denatured under reducing conditions, separated on 10%
sodium dodecyl sulfate (SDS) polyacrylamide gels, and
transferred to nitrocellulose by voltage gradient transfer.
HDAC1 and HDAC3 levels in proliferating and senescent WI-38 cellsFigure 8
HDAC1 and HDAC3 levels in proliferating and senescent WI-38 cells. Cytosolic and nuclear extracts were prepared 
from proliferating and senescent WI-38 cells. HDAC1 and HDAC3 levels were determined in both fractions by immunoblot-
ting. Actin served as a loading control. The results from duplicate cultures are shown.Page 8 of 11
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Specific proteins were detected with appropriate antibod-
ies using enhanced chemiluminescence detection (Santa
Cruz Biotechnology, Santa Cruz, CA). Immunoblotting
antibodies used were: subunit β1 PW8140, subunit β2
PW8145, subunit β3 PW8130, subunit β4 PW8890, subu-
nit β5 PW8895, subunit β6 PW9000, and subunit β7
PW8135, (Affiniti Research Products Ltd., Mamhead, Exe-
ter, UK); Ubiquitin P1A6, (Santa Cruz Biotechnology,
Santa Cruz, CA); p21 C-19, (Santa Cruz Biotechnology,
Santa Cruz, CA); and Actin I-19, (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). The antibodies specific for ubiquitin
and p21WAF1 were diluted 1:500 for immunoblotting. All
other antibodies were employed at a 1:1000 dilution. For
optical densitometry, immunoblot images were scanned
on a UMAX Astra 1220P scanner and analyzed with NIH
Image version 1.62. Statistical significance was deter-
mined by a paired Student's t-test.
Proteasome activity assay
Proteasome activity was quantified by using a fluorogenic
proteasome-specific substrate. The assay is based on the
detection of the fluorophore AMC (7-amino-4-methyl-
coumarin) after cleavage from the synthetic proteasome
substrate Suc-LLVY-AMC (Calbiochem, San Diego, CA).
Cytosolic extract (5 µg of total protein in 5 µl) was incu-
bated in a 100 µl reaction containing 20 mM Tris-HCL
(pH 7.8), 0.5 mM EDTA, 0.035% SDS, and 70 µM Suc-
LLVY-AMC for 10 minutes at room temperature. The
change in fluorescence (substrate consumption) was
measured over an interval of 40 minutes using a micro-
titer plate fluorometer (excitation, 360 nm; emission, 460
nm). Proteasome-independent activity was determined by
performing the assay in the presence of proteasome inhib-
itor MG-132 (final concentration 60 µM) (Calbiochem,
San Diego, CA). Proteasome activity values were derived
by subtracting the fluorescence obtained in the presence
of this inhibitor from the values obtained in its absence.
The values shown represent the ratio in proteasome activ-
ity from each sample compared to the activity in young
WI-38 cell extracts. Assays were performed in quadrupli-
cate, and statistical significance was determined by a
paired Student's t-test.
Senescence-associated β-galactosidase staining
Staining for β-galactosidase activity in WI-38 cells was per-
formed as previously described [29]. WI-38 cells were
washed with PBS, fixed in 0.2% glutaraldehyde/2% for-
maldehyde for 10 minutes at room temperature, and
washed again with PBS. Cells were then stained at 37°C
(in the absence of CO2) with fresh senescence-associated
β-gal (SA-β-gal) staining solution (150 mM NaCl, 2 mM
MgCl2, 5 mM potassium ferricyanide, 5 mM potassium
ferrocyanide, and 40 mM citric acid/sodium phosphate,
pH 6.0) containing 1 mg/ml 5-bromo-4-chloro-3-indolyl-
β-D-galactoside (X-gal). Once staining was maximal (12–
16 hrs), cells were washed with PBS and overlaid in 70%
glycerol. Images were taken at 100 × magnification as
viewed by phase contrast.
Abbreviations
HDAC, histone deacetylase; BA, butyrate; TSA, trichosta-
tin A; SA-β-gal, senescence-associated-β-galactosidase; E-
MEM, minimal essential media with Earle's salts; Suc-
LLVY-AMC, N-succinyl-Leu-Leu-Val-Tyr-7-amino-4-meth-
ylcoumarin.
Model: the age-related decline in HDAC levels contributes to replicative senescenceFigure 9
Model: the age-related decline in HDAC levels contributes to replicative senescence. As WI-38 cells enter senes-
cence, cellular HDAC activity is envisioned to decrease to alter gene expression. The reduction in HDAC activity induces the 
expression of p21WAF1 to assist in senescence-associated growth arrest. It is also envisioned that the decline in HDAC activity 
contributes to the senescence-associated drop in proteasome activity.Page 9 of 11
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